Elsevier

Pharmacological Research

Volume 117, March 2017, Pages 148-155
Pharmacological Research

Review
Gender related differences in treatment and response to statins in primary and secondary cardiovascular prevention: The never-ending debate

https://doi.org/10.1016/j.phrs.2016.12.027Get rights and content

Abstract

Statins are a main curbstone in the prevention of cardiovascular disease (CVD), pandemic in 21st century. CVD displays evident sex and gender differences, not only in clinical manifestation and outcomes but also in pharmacological treatment. Whether statin therapy should be differentially prescribed according to sex is a matter of debate. Aside a different pharmacological action, statins are not proven to be less effective in one gender comparing to the other, nor to be less safe. Nevertheless, up to date evidence shows that statins have not been adequately tested in women, especially in primary prevention trials. Since data-lacking, making a treatment decision on women is potentially harmful, although female individuals represent the majority of the population and they have a greater lifetime CVD risk. Therefore, adequately powered randomized control trials with longer follow-up are warranted to establish if a benefit on CV events and mortality prevention exists in both sexes. The aim of the present review is to summarize the sex and gender differences in statin use: it raises concerns and updates perspectives towards an evidence-based and sex-tailored prevention of CVD management.

Introduction

Cardiovascular disease (CVD) continues to be a prominent cause of mortality and morbidity throughout the world despite improvements in diagnosis and management. In the last decade, the mortality in men due to CVD has decreased substantially. The rate of cardiac deaths, primarily caused by coronary artery disease (CAD), is significantly higher in women compared to men (51 vs. 42%) [1]. Nevertheless, women are at lower risk for CVD than men; therefore, women require less urgent CVD prevention treatments, that include lipid-lowering or antiplatelet drugs [2]. In fact, women experience the first event of coronary heart disease (CHD) usually ten years later compared to men. Conversely, the incidence of CVD in women increases considerably for the lack of cardio-protective effect from ovarian hormones after menopause [3].

The pathogenesis of CVD is always multifactorial and is related to well-known risk factors. Changes in traditional cardiovascular (CV) risk factors, such as smoking, hypertension and dyslipidemia, are responsible for more than a 50% reduction in CV mortality in the general population [4]. Unfortunately, the control of these CV risk factors is still insufficient. Lipid abnormalities are the more prevalent risk factors in women, detectable in around 50% of cases [5]. Notably, premenopausal women are less affected by hypertension and have lower lipid levels than men of the same age, while the sex disparity disappears in the elderly [6]. Therefore, the impact of high cholesterol levels is typically observed after menopause but not in pre-menopause, where cholesterol levels can be acceptably elevated [5], [6].

Nowadays, cholesterol lowering agents [7], [8] are a cost-effective strategy to prevent CVD in individuals with high CV risk. Because statins provide the most effective pharmacologic approach to CVD risk reduction, a likely difference in sex-dependent response in CVD reduction and in lipid changes deserves to be deeply examined. However, women are underrepresented in statin trials, challenging the assessment of sex-related disparities in lipid response. The rate of female enrollment spreads from 14% to 69% in statin trials [9] and rarely sex-stratified analysis of outcomes are provided.

Available data indicate that statins are effective in women for secondary CVD prevention. Benefits outweigh disadvantages of statin therapy in those with a high CV risk, while several doubts exist for the primary prevention of women at low-intermediate CV risk.

Thus, the present review summarizes the sex and gender differences in statin use. It raises concerns and updates perspectives towards an evidence-based and sex-tailored prevention of CVD management.

Section snippets

Sex-dependent differences in pharmacology of statins

Statins are essential for the treatment and prevention of CVD. Their CV benefits are not exclusively linked to the lipid-lowering effect. Despite the reduction of low-density lipoprotein cholesterol (LDL-C) levels through the direct inhibition of the 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase, statins exert other advantageous and pleiotropic effects that help explaining their effectiveness in CVD prevention and treatment. These effects occur through the modulation of atherosclerosis

Statins’ adverse effects and gender differences

To date, no compelling data support that statins are more harmful for women than for men.

Some statin adverse effects, like skeletal muscle toxic damage and diabetes mellitus (DM), seem to be more common in women. Muscle toxicity is the primary adverse effect of statins [30]. Rhabdomyolysis is a rare side effect, whereas mild myalgia is quite common [31]. However, no standard definition for statin-dependent myotoxicity exists so that its real incidence is difficult to quantify. Although

Statins and CVD prevention trials

Sex-oriented evidence on statins' effectiveness and safety in women are poor [5]. Globally, interventional clinical trials reported improved CV outcomes in both men and women. Nevertheless, a critical and focused assessment of gender differences is mandatory to tailor the prevention strategies of CVD.

Secondary CVD prevention guidelines (Table 1)

The most recent American guidelines recommend high-intensity statin therapy in all individuals with documented atherosclerotic CVD and do not promote a specific LDL-C target as previously required by National Cholesterol Education Panel Adult Treatment Panel III [69] or by the latest European guidelines [70]. Specifically, 2013 ACC/AHA jointly released lipid guidelines recommend high-dose statin therapy (atorvastatin 40–80 mg or rosuvastatin 20–40 mg daily) in men and women aged  75 years, and

Conclusion

According to guidelines, women should be treated with statins for both primary and secondary CVD prevention, when the benefit outweighs the risk and after an individualized assessment for all patients. Unfortunately, the body of evidence supporting this approach is far to be conclusive.

Specifically, the gender-dependent efficacy of statin therapy in primary prevention is still debated, whereas the benefits of statins are sex-balanced in secondary prevention. Currently, physicians should

References (72)

  • B.M. Victor et al.

    Gender differences in achieving optimal lipid goals in patients with coronary artery disease

    Am. J. Cardiol.

    (2014)
  • R. Wolbold et al.

    Sex is a major determinant of CYP3A4 expression in human liver

    Hepatology

    (2003)
  • K. Kajinami et al.

    Gender-specific effects of estrogen receptor alpha gene haplotype on high-density lipoprotein cholesterol response to atorvastatin: interaction with apolipoprotein AI gene polymorphism

    Atherosclerosis

    (2005)
  • W.J. Kostis et al.

    Meta-Analysis of statin effects in women versus men

    J. Am. Coll. Cardiol.

    (2012)
  • N. Sattar et al.

    Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials

    Lancet (London England)

    (2010)
  • M. Petretta et al.

    Impact of gender in primary prevention of coronary heart disease with statin therapy: a meta-analysis

    Int. J. Cardiol.

    (2010)
  • P.Y. Hsue et al.

    Impact of female sex on lipid lowering, clinical outcomes, and adverse effects in atorvastatin trials

    Am. J. Cardiol.

    (2015)
  • J. Billimek et al.

    Understanding disparities in lipid management among patients with type 2 diabetes: gender differences in medication nonadherence after treatment intensification

    Women’s Health Issues

    (2015)
  • N.J. Stone et al.

    2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American college of cardiology/American heart association task force on practice guidelines

    J. Am. Coll. Cardiol.

    (2014)
  • R. Puri et al.

    Sex-related differences of coronary atherosclerosis regression following maximally intensive statin therapy: insights from SATURN

    JACC Cardiovasc. Imaging

    (2014)
  • S.M. Grundy et al.

    Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines

    J. Am. Coll. Cardiol.

    (2004)
  • L. Mosca et al.

    Effectiveness-based guidelines for the prevention of cardiovascular disease in women—2011 update: a guideline from the american heart association

    J. Am. Coll. Cardiol.

    (2011)
  • M. Nichols et al.

    Cardiovascular disease in Europe 2014: epidemiological update

    Eur. Heart J.

    (2014)
  • Q. Yang et al.

    Trends in cardiovascular health metrics and associations with all-cause and CVD mortality among US adults

    JAMA

    (2012)
  • M. Garcia et al.

    Cardiovascular disease in women: clinical perspectives

    Circ. Res.

    (2016)
  • EUGenMed Cardiovascular Clinical Study Group et al.

    Gender in cardiovascular diseases: impact on clinical manifestations, management, and outcomes

    Eur. Heart J.

    (2016)
  • A. McConnachie et al.

    Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study

    Eur. Heart J.

    (2014)
  • H. Mistry et al.

    Cost-effectiveness of a European preventive cardiology programme in primary care: a Markov modelling approach

    BMJ Open

    (2012)
  • R. Cangemi et al.

    Early decrease of oxidative stress by atorvastatin in hypercholesterolaemic patients: effect on circulating vitamin E

    Eur. Heart J.

    (2008)
  • P. Gelosa et al.

    The role of HMG-CoA reductase inhibition in endothelial dysfunction and inflammation

    Vasc. Health Risk Manag.

    (2007)
  • V.R. Taqueti et al.

    Excess cardiovascular risk in women relative to men referred for Coronary angiography is associated with severely impaired coronary flow reserve, not obstructive disease

    Circulation

    (2016)
  • P. Pignatelli et al.

    Immediate antioxidant and antiplatelet effect of atorvastatin via inhibition of Nox2

    Circulation

    (2012)
  • P. Quist-Paulsen

    Statins and inflammation: an update

    Curr. Opin. Cardiol.

    (2010)
  • G.M.C. Rosano et al.

    Gender differences in treatment of cardiovascular disease: a task force on gender of the ESC proposal on gender specific studies in cardiovascular pharmacology

    Fundam. Clin. Pharmacol.

    (2010)
  • G.M.C. Rosano et al.

    Gender differences in the effect of cardiovascular drugs: a position document of the Working Group on Pharmacology and Drug Therapy of the ESC

    Eur. Heart J.

    (2015)
  • G. Assmann et al.

    Gap between guidelines and practice: attainment of treatment targets in patients with primary hypercholesterolemia starting statin therapy. Results of the 4E-registry (Efficacy calculation and measurement of cardiovascular and cerebrovascular events including physicians' experience and evaluation)

    Eur. J. Cardiovasc. Prev. Rehabil.

    (2006)
  • Cited by (0)

    View full text